NEWARK, Calif., May 14, 2019 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced results from the initial single ascending dose (SAD) part of the Phase 1 study of PN-943, an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results